Does 7-OH show up on a DOT drug test?

At a glance: 7-OH and the DOT drug test

Key Takeaways

• 7-OH does not appear on a standard DOT 5-panel drug test because kratom alkaloids are not target analytes under 49 CFR Part 40, and they do not cross-react with the opiate immunoassays used in the panel.
• A specialized kratom assay can detect mitragynine and 7-OH in urine when specifically ordered. These are separate from the standard panel and must be added explicitly.
• On July 1, 2026, the DEA filed notices of intent to temporarily place 7-OH above a specified threshold in Schedule I of the Controlled Substances Act. The order was expected no earlier than August 5, 2026. This is a live regulatory situation; check current status before relying on this article for compliance decisions.
• For CDL holders who have developed a dependence on 7-OH, buprenorphine-based treatment is an evidence-based option and also does not appear on the standard DOT 5-panel. Under current FMCSA guidance, buprenorphine is no longer automatically disqualifying, though medical examiner discretion applies.

How the DOT 5-panel drug test works

The DOT 5-panel is a federally standardized urine drug test required under 49 CFR Part 40 for anyone performing safety-sensitive functions in federally regulated transportation roles. This covers commercial truck drivers (regulated by the FMCSA), airline pilots (FAA), railroad workers (FRA), transit employees (FTA), pipeline workers (PHMSA), and Coast Guard mariners.

The panel screens for five drug categories, established by the Department of Transportation in coordination with the Department of Health and Human Services. Under 49 CFR Part 40, §40.82, the required substances are:

The panel is fixed. Employers regulated by DOT agencies cannot add or remove substances for federally mandated testing. Testing must be performed at SAMHSA-certified laboratories. The specific opioids the panel targets are morphine-class compounds. Kratom alkaloids are not on this list.

Why 7-OH does not trigger the opioid category

The opioid portion of the DOT 5-panel uses immunoassay technology calibrated to detect morphine-type opioids. These immunoassays work by using antibodies that bind to the target drug or its metabolites. For the opiate/opioid panel, those antibodies are designed around morphine, codeine, and related semi-synthetic compounds.

Mitragynine and 7-OH are chemically classified as indole alkaloids, not opiates. Although they act on opioid receptors in the brain, their molecular structure is fundamentally different from morphine-class compounds. Research confirms that cross-reactivity with standard opiate immunoassays is negligible at typical use concentrations: kratom is "not misidentified, but usually missed" on standard panels because the antibodies simply do not bind to it.

A 2020 study in the American Journal of Clinical Pathology found that kratom alkaloids could produce cross-reactivity on one specific assay (the EDDP methadone metabolite immunoassay) at very high concentrations in spiked lab samples, but this was assay-specific and not applicable to the standard opioid panels used in DOT testing. The DOT panel targets morphine-class opioids, not methadone metabolites, and that specific interaction does not carry over.

The plain-language answer: 7-OH does not appear on a standard DOT 5-panel drug test because kratom's alkaloids are not among the substances the panel screens for, and they do not chemically resemble the substances it does screen for.

When 7-OH can be detected

Kratom alkaloids can be detected when a specialized kratom assay is specifically ordered as a separate test outside the standard 5-panel. Several major clinical laboratories offer dedicated mitragynine/7-OH testing. The Altiscreen testing analysis notes that Labcorp offers a dedicated kratom immunoassay screen at a 5.0 ng/mL cutoff, followed by LC-MS/MS confirmation.

These specialized tests are not part of the DOT program. They are used in clinical settings (treatment programs monitoring for kratom use), forensic contexts, and by employers in safety-sensitive industries who have chosen to add kratom to their non-DOT testing programs.

Detection windows for specialized testing vary by dose, frequency, and product potency:

One additional risk for people using unregulated kratom extracts: some products sold at gas stations and online have been found adulterated with actual controlled substances, including fentanyl. A positive DOT drug test in that case would reflect the adulterant, not 7-OH. The career consequence of a verified positive for fentanyl is the same regardless of what the driver thought they were using.

What this means for commercial drivers

A clean DOT screen does not mean 7-OH is safe or permitted for CDL holders. Several distinct issues apply:

Impairment. 7-OH is a potent mu-opioid receptor agonist. The FDA's July 2025 announcement described concentrated 7-OH products as opioid compounds posing meaningful risks including sedation, respiratory depression, dependence, and withdrawal. A driver using concentrated 7-OH extracts is using a substance with real impairment potential behind the wheel, regardless of whether a test detects it.

Regulatory status. As of July 6, 2026, the DEA published notices of intent in the Federal Register to temporarily place 7-OH above a specified threshold in Schedule I of the Controlled Substances Act. The Federal Register notice indicated the temporary order would not be issued before August 5, 2026, with a public comment period running through July 31, 2026. This is a fast-moving regulatory situation. Once a temporary Schedule I order takes effect, manufacture, distribution, sale, and possession of covered 7-OH products would become subject to the criminal, civil, and administrative provisions of the Controlled Substances Act.

Medical certification. FMCSA medical examiners evaluate driver fitness for duty, including prescription and non-prescription substance use. The FMCSA Medical Examiner's Handbook (2024 Edition) instructs examiners to assess whether any substance a driver uses could impair safe operation. Honesty on the medical examination report (Form MCSA-5875) is required. Using an unregulated opioid compound outside any medical framework, and one that a federal agency has moved to restrict, creates real exposure at the physical examination regardless of test panel results.

FMCSA regulations under 49 CFR Part 391.41 prohibit drivers from using any substance that could affect safe operation of a commercial motor vehicle, not only those that appear on the 5-panel.

If you are a driver struggling with 7-OH dependence

Many drivers avoid seeking help because they fear losing their medical card. That fear is understandable, but the path to keeping your certification runs through treatment and stability, not through avoiding care.

Buprenorphine/naloxone (Suboxone) is the FDA-approved standard of care for opioid use disorder and is effective for dependence on opioid-acting substances including 7-OH. It also does not appear on the standard DOT 5-panel.

Under current FMCSA guidance, buprenorphine is no longer automatically disqualifying for CDL holders. A driver who is stable on buprenorphine, not impaired, and supported by documentation from a prescribing clinician can still potentially qualify for medical certification. The outcome is examiner-dependent and not guaranteed; some examiners remain cautious. Certification requires candor, clinical documentation of stability, and a prescriber who can speak to your fitness for duty.

This is a decision to make with a licensed clinician who understands both OUD treatment and the DOT medical certification process, not a plan to navigate alone.

Frequently Asked Questions

Does kratom show up on a DOT drug test?

No. Kratom alkaloids, including mitragynine and 7-OH, are not among the substances tested under the DOT 5-panel and do not cross-react with the opioid immunoassays used in the panel at typical use concentrations. The DOT panel screens for marijuana, cocaine, amphetamines, specific opioids (morphine, codeine, heroin, oxycodone, hydrocodone), and PCP under 49 CFR Part 40. Kratom is not a target analyte and was not added to the updated SAMHSA mandatory testing guidelines effective July 2025.

Can my employer test me for kratom even if the DOT panel doesn't include it?

Yes, with conditions. DOT-regulated employers cannot modify the federally mandated 5-panel for their DOT testing program. However, employers can conduct a separate, non-DOT drug test alongside the required DOT test and include additional substances, such as kratom, in that non-DOT program. A growing number of employers in safety-sensitive industries are adding kratom assays to their non-DOT panels. The two programs are legally distinct, but both can affect your employment.

Will 7-OH cause a false positive for opioids on a drug test?

Almost certainly not at typical use concentrations on a standard DOT panel. Kratom alkaloids are structurally distinct from morphine-class opioids. Research confirms that cross-reactivity on standard opiate immunoassays is negligible at typical use levels. If you receive an unexpected positive on the opioid panel, request confirmation by GC-MS or LC-MS/MS, which will identify the specific compound. Kratom alkaloids confirmed by mass spectrometry are reported as mitragynine or 7-OH, not as morphine or codeine.

Does buprenorphine show up on a DOT drug test?

No. Buprenorphine is not a target analyte on the standard DOT 5-panel. It does not cross-react with the opioid immunoassays used in DOT testing. Some expanded non-DOT employer panels do include buprenorphine, but for the federally mandated DOT program under 49 CFR Part 40, buprenorphine does not appear.

Is 7-OH legal right now?

As of July 20, 2026, the DEA has published a notice of intent to temporarily place 7-OH above a specified threshold in Schedule I, but the temporary order had not yet taken effect. The Federal Register notice indicated the order would not be issued before August 5, 2026. The public comment period runs through July 31, 2026. Florida placed concentrated 7-OH in Schedule I under state law effective June 22, 2026. Multiple other states ban 7-OH or kratom under separate state statutes. This is a fast-changing situation; confirm current federal and state status before making any decisions based on it.

What should I do if I think I am dependent on 7-OH?

Talk to a licensed clinician. 7-OH dependence follows the same physiological pattern as opioid dependence generally, and FDA-approved medications exist to treat it safely. Buprenorphine/naloxone is the most accessible option and can be started through a telehealth visit in most states. For drivers specifically, connecting with a provider who understands both the clinical and regulatory picture gives you the best chance of managing treatment while protecting your certification. Learn how Bicycle Health's online treatment works.